Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing oncology therapies by improving the safety, tolerability, and efficacy of existing cancer drugs through proprietary chemistry and regulatory strategies. The company operates within the biotechnology and pharmaceutical research and development industries, with a primary emphasis on oncology drug development. Its approach centers on modifying known cancer agents to reduce dose-limiting toxicities while maintaining or enhancing therapeutic activity.
The company’s core value proposition lies in its Regulatory Science Platform, which leverages established regulatory pathways and historical clinical data to potentially accelerate development timelines and reduce development risk. Processa Pharmaceuticals was incorporated in 2011 and became publicly traded in 2019 through a reverse merger, subsequently listing its common stock on the Nasdaq under the ticker symbol PCSA. Since inception, the company has remained pre-revenue and focused on advancing its pipeline through clinical development.
Business Operations
Processa Pharmaceuticals’ operations are organized around the research and clinical development of drug candidates, with no commercial manufacturing or product sales to date. The company’s pipeline consists of internally developed oncology assets, including PCS499, PCS3117, PCS12852, and PCS6422, each targeting specific cancer indications or cancer-related complications. Revenue generation has not yet commenced, and operating expenses are primarily driven by research and development costs, clinical trial activities, regulatory preparation, and general corporate functions.
The company conducts its development activities primarily through third-party contract research organizations and academic collaborators, rather than maintaining large internal laboratory or manufacturing facilities. Processa does not currently report material international revenue operations, and its assets consist mainly of intellectual property, clinical data, and regulatory documentation associated with its drug candidates. No material joint ventures have been disclosed, though the company maintains research and clinical relationships necessary to advance trials.
Strategic Position & Investments
Processa Pharmaceuticals’ strategic direction is centered on advancing its lead and follow-on oncology candidates through early- and mid-stage clinical trials, with the goal of securing strategic partnerships, licensing arrangements, or acquisition opportunities. The company prioritizes indications with significant unmet medical need and where existing therapies are limited by toxicity, allowing its reformulated or chemically modified compounds to potentially differentiate from standard treatments.
Investment activity is primarily internal, focused on funding clinical trials and regulatory development rather than acquiring external companies. The company has not announced major acquisitions but continues to invest in expanding its intellectual property portfolio around its drug candidates. Its pipeline reflects engagement in emerging oncology areas such as combination cancer therapies and treatments aimed at mitigating cancer treatment-related complications.
Geographic Footprint
Processa Pharmaceuticals is headquartered in Hanover, Maryland, United States, and its operations are primarily based in the United States. Clinical development activities, including patient enrollment and trial management, may involve multiple sites within the U.S. and, in some cases, international locations depending on trial design, though the company does not maintain significant foreign offices.
The company’s market focus is global in scope, consistent with the international nature of oncology drug development and regulatory approvals, but its operational footprint remains concentrated in North America. Any international presence is largely indirect, facilitated through clinical research organizations and regulatory interactions rather than owned facilities.
Leadership & Governance
Processa Pharmaceuticals is led by executives with backgrounds in pharmaceutical development, regulatory science, and corporate management. The leadership team emphasizes disciplined capital allocation, regulatory expertise, and a development strategy designed to reduce clinical and regulatory risk. The company operates under a board-governed structure typical of U.S. public biopharmaceutical firms.
Key executives include:
- David Young – Chief Executive Officer
- David S. Block, Ph.D. – President and Chief Scientific Officer
- Barry D. Quart, Pharm.D. – Chairman of the Board
- Todd A. Keeler – Chief Financial Officer
The leadership’s strategic vision is centered on leveraging regulatory knowledge and scientific expertise to advance oncology assets efficiently while seeking value-creating partnerships or transactions as clinical data matures.